EASD 2026: TRIUMPH-2 data puts retatrutide above the incretin ceiling in T2D
On 30 September, at the 62nd Annual Meeting of the European Association for the Study of Diabetes (EASD) in Milan,…
Cardiovascular
-
-
EASD 2026: Petrelintide pairs 10.7% weight loss with placebo-like GI tolerability
On September 30, at the 62nd Annual Meeting of the European Association for the Study of Diabetes (EASD) in Milan,…
-
EASD 2026: Semaglutide dose escalation shows lower CV risk vs tirzepatide in diabetes
This year at the European Association for the Study of Diabetes (EASD) Annual Meeting, real-world data compared cardiovascular outcomes with…
-
ESC 2026: AstraZeneca’s oral relaxin agonist succeeds in Phase II trial
AstraZeneca’s oral relaxin agonist improved cardiac function in patients with chronic heart failure in a Phase IIb trial. In data…
-
ESC 2026: Head-to-head study compares inclisiran and bempedoic acid
This year at the European Society of Cardiology (ESC) Scientific Sessions, results from the Phase IV VICTORION-CHALLENGE trial provided the…
-
ESC 2026: Congress brings key readouts across the cardiovascular space
With the 2026 European Society of Cardiology (ESC) Congress in full swing, cardiologists and industry titans alike are gathering in…
-
Milestone’s etripamil nasal spray enters Phase III trial for atrial fibrillation
Milestone Pharmaceuticals has commenced a pivotal Phase III trial of its etripamil nasal spray aimed at treating atrial fibrillation with…
-
Tenax Therapeutics’ stock crashes on Phase III trial failure
Tenax Therapeutics’ stock dropped by nearly 90% after a Phase III trial of its oral therapy for pulmonary hypertension associated…
-
Placental abruption could increase risk of cardiovascular disease in women
Cardiovascular disease (CVD) is the leading cause of death globally, with the World Health Organization (WHO) estimating that 19.8 million…
-
Smartwatches could aid in monitoring heart failure exacerbations
Heart failure (HF) is a substantial global health problem that is characterised by significant mortality and poor quality of life.…
